The net profit for the year-ago period stood at Rs 531 crore and the revenue from operations was reported at Rs 2,259 crore.
Additionally, the board of directors of the company has also announced a dividend of Rs 30 per share for its shareholders for the financial year 2024-25. For the purpose of the shareholders, the company has fixed July 25 as the record date.
Sequentially, the PAT rose by 12.28%, up from Rs 594 crore in the third quarter of FY25. Even on the revenue front, the company registered a 10.3% QoQ growth, climbing up from Rs 2,297 crore.
Further, Divi’s Laboratories reported a consolidated total income of Rs 2,671 crore for the quarter ended March 31, 2025, compared to Rs 2,382 crore in the same quarter last year.
For the current quarter, the company has a forex gain of Rs 10 crore as against a forex loss of Rs 2 crore for the corresponding quarter of the previous year.Meanwhile, for the full financial year 2025, the company’s PAT stood at Rs 2,191 crore, versus Rs 1,600 crore for the corresponding quarter of the previous financial year, marking a growth of 36.9% YoY.Also read: What does CLSA’s downgrade mean for IndusInd Bank’s future?Regarding its capex programs, the company informed that its Unit III greenfield project at Ontimamidi Village, near Kakinada, Andhra Pradesh, has commenced commercial operations in the current quarter.
Divi’s Labs has capitalised assets valuing Rs 1,118 crore during the financial year, of which Rs 755 crore pertaining to Unit-III at Kakinada.
On Friday, the shares of Divi’s Laboratories closed 1.16% higher at Rs 6,281.35 on the BSE.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
